SCHEMBL250458

SCHEMBL250458

CCN[C@H](C(=O)O)[C@@H](C)CC

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.59
L3MBTL1 Q9Y468 1/20 0.50
FPR2 P25090 2/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
ATM Q13315 1/20 0.44
MME P08473 2/20 0.42
ACE P12821 2/20 0.42
CPA1 P15085 2/20 0.42
ACE2 Q9BYF1 2/20 0.42
CA2 P00918 2/20 0.41
CA1 P00915 1/20 0.41
ENPEP Q07075 2/20 0.40
MAPK1 P28482 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30552195 1.00 ALDH1A1 (0.59) ALDH1A1L3MBTL1FPR2MEN1KMT2A
SCHEMBL250457 1.00 ALDH1A1 (0.59) ALDH1A1L3MBTL1FPR2MEN1KMT2A
SCHEMBL21417705 0.84 ALDH1A1 (0.42) ALDH1A1L3MBTL1FPR2MEN1KMT2A
SCHEMBL24932734 0.84 ALDH1A1 (0.42) ALDH1A1L3MBTL1FPR2MEN1KMT2A
SCHEMBL10062994 0.84 ALDH1A1 (0.42) ALDH1A1L3MBTL1FPR2MEN1KMT2A
SCHEMBL1319707 0.83 SMN1; SMN2 (0.44) ALDH1A1L3MBTL1MAPK1
SCHEMBL1319709 0.83 SMN1; SMN2 (0.44) ALDH1A1L3MBTL1MAPK1
SCHEMBL16640683 0.82 ALDH1A1 (0.41) ALDH1A1L3MBTL1FPR2MEN1KMT2A
SCHEMBL12301656 0.82 ALDH1A1 (0.41) ALDH1A1L3MBTL1FPR2MEN1KMT2A
SCHEMBL14374026 0.82 ALDH1A1 (0.41) ALDH1A1L3MBTL1FPR2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250268982-A1 COMPOSITIONS AND METHODS FOR TREATMENT AND/OR PROPHYLAXIS OF PROTEINOPATHIES REGAIN THERAPEUTICS SWEDEN AB (SE) 2025-08-28 US claimed
EP-4347628-A2 COMPOSITIONS AND METHODS FOR TREATMENT AND/OR PROPHYLAXIS OF PROTEINOPATHIES Regain Therapeutics Sweden AB (SE) 2024-04-10 EP claimed
CN-117858892-A Compositions and methods for treating and/or preventing proteinopathies 恢复治疗瑞典公司 2024-04-09 CN claimed
WO-2022248650-A2 COMPOSITIONS AND METHODS FOR TREATMENT AND/OR PROPHYLAXIS OF PROTEINOPATHIES REGAIN THERAPEUTICS SWEDEN AB (SE) 2022-12-01 WO claimed
CN-112351818-A Crystalline salts of 5-methyl- (6S) -tetrahydrofolic acid and ethyl L-isoleucine 默克专利股份有限公司 2021-02-09 CN claimed
US-20250295713-A1 COMPOSITIONS AND METHODS FOR IMPROVING SKIN HEALTH AND FOR THE TREATMENT AND PREVENTION OF DISEASES, DISORDERS AND CONDITIONS ASSOCIATED WITH PATHOGENIC MICROBES DERMBIONT, INC. 2025-09-25 US disclosed
US-20250268982-A1 COMPOSITIONS AND METHODS FOR TREATMENT AND/OR PROPHYLAXIS OF PROTEINOPATHIES REGAIN THERAPEUTICS SWEDEN AB (SE) 2025-08-28 US disclosed
US-12064459-B2 Compositions and methods for improving skin health and for the treatment and prevention of diseases, disorders and conditions associated with pathogenic microbes DERMBIONT, INC. (US) 2024-08-20 US disclosed
US-20240182532-A1 MICROPEPTIDES AND USES THEREOF FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÒGICA DE VALL HEBRON (ES) 2024-06-06 US disclosed
EP-4347628-A2 COMPOSITIONS AND METHODS FOR TREATMENT AND/OR PROPHYLAXIS OF PROTEINOPATHIES Regain Therapeutics Sweden AB (SE) 2024-04-10 EP disclosed
CN-117858892-A Compositions and methods for treating and/or preventing proteinopathies 恢复治疗瑞典公司 2024-04-09 CN disclosed
US-11858972-B2 Micropeptides and uses thereof FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÒGICA DE VALL HEBRON (ES) 2024-01-02 US disclosed
US-20080305471-A1 polypeptides comprising an amino acid sequence of a photocatalytic unit of a photosynthetic microorganism, capable of maintaining photocatalytic activity when attached to solid surfaces of electrooptic devices RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) 2008-12-11 US disclosed
EP-1677816-A1 THERAPEUTIC METHOD MONASH UNIVERSITY (AU) 2006-07-12 EP disclosed
WO-2005032578-A1 THERAPEUTIC METHOD MONASH UNIVERSITY (AU) 2005-04-14 WO disclosed
CN-1211188-A Urogenital and intestinal compositions PROCTER & GAMBLE (US) 1999-03-17 CN disclosed
CN-1211189-A Urogenital and intestinal disorder compositions comprising a substrance derived from plant species of the ericaceae family and a lactic acid bacteria growth factor PROCTER & GAMBLE (US) 1999-03-17 CN disclosed
EP-0880354-A1 UROGENITAL AND INTESTINAL COMPOSITIONS THE PROCTER & GAMBLE COMPANY (US) 1998-12-02 EP disclosed
WO-1997029762-A1 UROGENITAL AND INTESTINAL COMPOSITIONS THE PROCTER & GAMBLE COMPANY (US) 1997-08-21 WO disclosed
EP-0642530-A1 DERIVATIVES OF DOLASTATIN BASF Aktiengesellschaft (DE) 1995-03-15 EP disclosed